Dr James Miskin is Chief Technical Officer at Oxford BioMedica Plc. James obtained his Ph.D in bacterial molecular biology in 1995 from the University of Leeds, UK. He then worked for over five years as a post‐doctoral research scientist at the UK government‐funded Institute for Animal Health, investigating viral‐host interactions of the haemorrhagic pathogen African Swine Fever Virus. James then joined Oxford BioMedica (OXB) in December 2000 as a specialist in molecular virology. Since that time he has worked in a number of research and development areas, in particular developing methods to investigate the safety profile of lentiviral vectors, and is a named inventor on several patents in the field. James has significant experience in GxP assay development, routine testing, manufacturing, manufacturing development and analytical development. In his current role as Chief Technical Officer, he is a member of the company’s senior executive team (SET) with overall leadership responsibility for two teams within the Company: Manufacturing and Manufacturing Development. The Manufacturing team is responsible for routine GMP production, supply chain and oversight of technical programmes with our strategic partners, including Novartis and Sanofi. The Manufacturing development team is responsible for manufacturing process development, technical support, new process introduction and technology transfer (for internal and partnership manufacturing).
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.